New breathing drug ENA-001 enters first human safety tests

NCT ID NCT06967259

Recruiting now Symptom relief Sponsor: Enalare Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 26, 2026 · Updated 26 times

Summary

This early-stage study tests a new drug called ENA-001 in 36 healthy adults to see if it is safe and how the body processes it. The drug is given as a single shot into a vein or muscle and aims to help with respiratory depression (dangerously slow or weak breathing). The main goal is to check for side effects and measure breathing patterns.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinilabs
ACTIVE_NOT_RECRUITING

Eatontown, New Jersey, 07724, United States
Dr. Vince Clinical Research
COMPLETED

Overland Park, Kansas, 66212, United States
South Florida Research Phase I-IV
RECRUITING

Miami, Florida, 33166, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RESPIRATORY DEPRESSION